Tag: GLP-1 vs SGLT2 Combination Therapy

All studies mentioned in the article are referenced below. Chronic kidney disease (CKD) costs over $100 billion USD every year, yet effective therapies remain sparse. Into this fiscal and human crisis steps the glucagon-like peptide-1 (GLP-1) receptor axis, a metabolic signal which may prove to be a renal survival pathway. A study by Heerspink et…